Chemistry:IM-250
From HandWiki
IM-250 is an anti-herpetic drug candidate[1] developed by Innovative Molecules Gmbh.[2] The drug was conceived by a chemist at the company, who hypothesized that swapping the sulfonamide functional group of pritelivir for a sulfoximine would reduce off-target effects. In addition, the pyridine ring on pritelivir was changed to a 2,5-difluorobenzene ring to make the drug candidate more likely to enter the central nervous system as herpes can lie dormant within neurons.[3]
Innovative Molecules raised 20 million euro for clinical trials on humans.[4]
See also
References
- ↑ Gege, Christian; Bravo, Fernando J.; Uhlig, Nadja; Hagmaier, Timo; Schmachtenberg, Rosanne; Elis, Julia; Burger-Kentischer, Anke; Finkelmeier, Doris et al. (16 June 2021). "A helicase-primase drug candidate with sufficient target tissue exposure affects latent neural herpes simplex virus infections". Science Translational Medicine 13 (598). doi:10.1126/scitranslmed.abf8668. PMID 34135112.
- ↑ "Drug Candidate Shows 'Potent Anti-Herpes Activity'". 17 June 2021. https://scienceblog.cincinnatichildrens.org/drug-candidate-shows-potent-anti-herpes-activity/.
- ↑ "Small molecule fights active and latent herpes infections in rodents". 21 January 2025. https://cen.acs.org/pharmaceuticals/drug-discovery/Small-molecule-fights-active-latent/99/i23.
- ↑ Lücking, Ulrich (7 October 2022). "New Opportunities for the Utilization of the Sulfoximine Group in Medicinal Chemistry from the Drug Designer's Perspective". Chemistry – A European Journal 28 (56). doi:10.1002/chem.202201993. PMID 35789054. Bibcode: 2022ChEuJ..28E1993L. https://chemrxiv.org/engage/chemrxiv/article-details/6284b5a844bdd53592675638.
 |  |
